Delighted to share our new paper, led by our recent PhD graduate and star scientist 🌟 @michelletran9.bsky.social.

Excited to share the final first-author paper of my PhD is online in Cancer Discovery @aacrjournals.bsky.social! doi.org/10.1158/2159...

We identify an SPP1⁺ macrophage–IL-6–CRP inflammatory axis linked to resistance to checkpoint blockade in bladder cancer
@bhardwajlab.bsky.social

Genome modelling and design across all domains of life with Evo 2 - Nature Evo 2 is an artificial intelligence-based biological foundation model trained on 9 trillion DNA base pairs spanning all domains of life that predicts functional properties from genomic sequences and provides a rich generative model for researchers in biology.

A paper published in Nature presents Evo 2: an artificial intelligence-based biological foundation model trained on 9 trillion DNA base pairs spanning all domains of life that predicts functional properties from genomic sequences and provides a rich generative model for researchers in biology. 🧪

The promises and challenges of neoantigen cancer vaccines - Nature Biotechnology Surveying recent progress in neoantigen cancer vaccine development, this Review highlights areas where further technological advances and optimized trial design could enhance clinical impact.

www.nature.com/articles/s41...

Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial - Nature Medicine In a prespecified ancillary analysis of the COSMOS randomized trial, supplementation with daily multivitamins, but not with cocoa extract, over the course of 2 years decreased biological aging, as mea...

Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial

www.nature.com/articles/s41...

Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier Garg et al. report that blocking the molecule SEMA4D strengthens immune responses against HER2-positive breast cancer. When paired with specialized dendritic cells, this approach boosts anti-tumor imm...

Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier

www.cell.com/cell-reports...

TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how T-cell receptors (TCRs) are generated through somatic recombination of variable (V), diversity (D), and joining (J) gene segments, resulting in an extraordinarily diverse receptor repertoire that is e...

TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how
jitc.bmj.com/content/14/3...

CD8+ T cells are primed by cDC1 and exacerbate tau-mediated neurodegeneration
www.biorxiv.org/content/10.6...

International Course of Immunotherapy March 23-25, 2026 11th Edition Theme: Targeting Immune Aging | Time: 9:00am-1.15pm NYC; 14:00-18.15h Paris; 10:00am-2.15pm Sao Paulo

At Immunoschool, @gitlinlabmsk.bsky.social will show how VEXAS syndrome is reshaping our understanding of immune aging, late-onset inflammatory disease & new routes to immunotherapy. A powerful 🔗 between clonal hematopoiesis & systemic inflammation.

Register FREE: www.eventbrite.com/e/internatio...

From mutant mice to meaningful signals: Read about Nobel laureate Fred Ramsdell’s #AACRIO26 keynote on regulatory T cells and immune tolerance on the #AACRBlog: buff.ly/N6PBOS4 #AACRBlog

Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response - PubMed Whether a T-cell response to dead cells arises depends on whether they harbor recognizable antigens, but also how dead cell debris impacts conventional dendritic cells (cDCs). In all tissues, cell debris is continuously phagocytosed by cDCs that can migrate to lymph nodes (LNs) and initiate T-cell r …

Phagocytosis of necroptotic cells optimizes type 1 conventional dendritic cells for induction of a cytotoxic T-cell response.
pubmed.ncbi.nlm.nih.gov/41764333/

TOX has opposing functions in CD4 & CD8 T cells, driving exhaustion in the latter but promoting Th1 commitment in CD4 T cells that drive antitumor immunity and pathogenic autoimmune responses
www.nature.com/articles/s41...
@natimmunol.nature.com @mskcancercenter.bsky.social

Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines Messenger RNA (mRNA) vaccines in lipid nanoparticles (LNPs) are effective, yet immunity can wane, and reactogenicity increases with dose. We integrate ionizable lipid design, LNP formulation, and untr...

Comprehensive Engineering of Ionizable Lipid Nanoparticles and mRNA Elements for Next-Generation Vaccines

pubs.acs.org/doi/10.1021/...

Pancreatic-targeted lipid nanoparticles based on organ capsule filtration - Nature Elucidation of fundamental pancreatic-targeted mechanisms enables the development of lipid nanoparticles for the precise delivery of nucleic acid therapeutics to the pancreas, highlighting their promi...

Pancreatic-targeted lipid nanoparticles based on organ capsule filtration
www.nature.com/articles/s41...

Join @pennmedicine.bsky.social for the Lynch Syndrome Symposium on 3/10 ft'ing keynote speaker @bhardwajlab.bsky.social (Mount Sinai Tisch Cancer Center)! Learn more & register➡️ tinyurl.com/yy6j5nbm

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC - Nature In a phase 1 trial, personalized mRNA vaccines tailored to individual tumour mutations in triple-negative breast cancer induced robust, long-lasting T cell responses and improved prognosis.

The unfounded move by HHSGov against mRNA vaccines will hurt our future potent immune therapy vs cancer. Another point of progress for triple-negative breast cancer with individualized neoantigen mRNA vaccines today

Adds to pancreatic, renal cell, melanoma reports
nature.com/articles/s41...

At the 2026 AACR IO Conference, Fred Hutch's Megan Othus presented research showing that the timing of immunotherapy infusions does not affect patient outcomes. Dr. Othus' analysis contradicts... At the 2026 AACR IO Conference, Fred Hutch's Megan Othus presented research showing that the timing of immunotherapy infusions does not affect patient outcomes. Dr. Othus' analysis contradicts recent ...

www.linkedin.com/posts/americ...

Nature Medicine to investigate study that found cancer treatment is better in morning Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning.

www.statnews.com/2026/02/20/c...

Cancer vaccines are here, and research is identifying how to push T cells even further so they thrive in the tumor microenvironment. Learn more about the opening‑night #AACRIO26 keynote addresses from #AACRFellows Elizabeth Jaffee and Philip Greenberg on the #AACRBlog: buff.ly/uKglwKq

Amazing last day of #AACRIO @theaacr.bsky.social we enjoyed closing out with Mansi Saxena presenting some of our latest clinical vaccine research and Ross Ward giving a talk on his preclinical vaccine project!

Two of our postdocs Guillaume Mestrallet and Ross Ward presenting their work today at AACR IO! @theaacr.bsky.social Please join us at Major Symposium 9 tomorrow morning to hear more about Ross's research! 🧬

AACR Immuno-Oncology Conference—Discovery and Innovation in Cancer Immunology: Dr. Antoni Ribas AACR Immuno-Oncology Conference cochair Antoni Ribas, MD, PhD, discusses what makes the meeting – #AACRio26 – unique , what he's excited about in the field, and the impact of immunotherapy on…

AACR Immuno-Oncology Conference cochair Antoni Ribas discusses what makes #AACRio26 unique, what he's excited about in the field, and the impact of immunotherapy on patients with cancer. buff.ly/ohArRho

#AACRIO26 chairs Nina Bhardwaj and Antoni Ribas welcome attendees to the AACR IO Conference on Discovery and Innovation in Cancer Immunology this evening in Los Angeles.

We’re getting excited for AACR IO 2026 in Los Angeles (Feb 18–21)! Bhardwaj Lab members will be giving talks and presenting posters. Please come find us there to chat about dendritic cells, immunotherapy, and cancer vaccines. @theaacr.bsky.social www.aacr.org/meeting/aacr...

Preprint: Targeting Neoantigens Conserved Across Organs and Species Overcomes Tumor Immune Escape @bhardwajlab.bsky.social @sinaiimmuno.bsky.social
papers.ssrn.com/sol3/papers....

AACR IO: Revolutionizing Treatment through Immunotherapy The AACR’s immuno-oncology meeting in Los Angeles, Feb. 23-26, 2025, brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.

The inaugural AACR IO Conference on Discovery and Innovation in Cancer Immunology takes place February 23-26 in Los Angeles. Learn why Dr. Antoni Ribas says #AACRIO25 is “the must-attend immuno-oncology event of the year." 
www.aacr.org/about-the-aa... 
#AACRStories

3. What the field needs next to move from “promising trials” → standard of care.
Kudos to first author Sayali Onkar + co-authors Mansi Saxena and Cansu Cimen Bozkus.
Hope you find this review insightful and energizing for the future of cancer vaccines. Read here: www.cell.com/cell-reports... (4/4)

1. Why vaccine monotherapy often underperforms in advanced disease and the growing promise of combinations (especially with immune checkpoint inhibitors)
2. Key bottlenecks: neoantigen prediction, antigen selection, manufacturing timelines (3/4)

Over the past decade, therapeutic cancer vaccines—especially neoantigen-based approaches—have rapidly evolved thanks to advances in sequencing, antigen prediction, and delivery platforms. In this review, we synthesize the latest clinical trial data and discuss: (2/4)

Pipe dream to pipeline: Journey of cancer vaccines and the road ahead Onkar et al. discuss the current landscape of therapeutic cancer vaccines in the context of recent clinical trials, with a special focus on neoantigen vaccines. They also highlight challenges and scop...

Excited to share our review "Pipe dream to Pipeline: Journey of cancer vaccines and the road ahead" that is now published in Cell Reports Medicine by Cell Press! (1/4)